The HR for overall survival of different adjunctive therapies in the entire population and subgroups, and sensitivity analysis for patients who died after surgery in the treatment groups in which surgery was first in the sequence of therapy
| NACRT HR (95%CI)* | ACRT HR (95%CI)* | ACh HR (95%CI)* | PCh | |
| All patients | ||||
| 1.163 (1.006 to 1.344) | 0.928 (0.856 to 1.006) | 1.243 (1.134 to 1.363) | 1 | |
| P value | 0.041 | 0.069 | <0.001 | |
| All patients (excluding patient who died after surgery in ACRT and ACh) | ||||
| Excluding subjects who died ≤30 days after surgery | 1.164 (1.006 to 1.345) | 0.923 (0.852 to 1.000) | 1.241 (1.131 to 1.361) | 1 |
| P value | 0.041 | 0.051 | <0.001 | |
| Excluding subjects who died ≤90 days after surgery | 1.165 (1.007 to 1.348) | 0.917 (0.845 to 0.994) | 1.194 (1.088 to 1.311) | 1 |
| P value | 0.040 | 0.035 | <0.001 | |
| Proximal | 1.101 (1.006 to 1.204) | 1.000 (0.891 to 1.121) | 1.291 (1.118 to 1.491) | 1 |
| P value | 0.036 | 0.99 | <0.001 | |
| Distal | 0.890 (0.796 to 0.996) | 1.215 (1.075 to 1.373) | 1 | |
| P value | 0.042 | 0.002 | ||
*Based on Cox regression model with propensity score matching and adjusted for surgical margin, regional lymph nodes examined, and lymphovascular invasion.
ACh, adjuvant chemotherapy; ACRT, adjuvant chemoradiation; NACRT, neoadjuvant chemoradiation; PCh, perioperative chemotherapy.